202 related articles for article (PubMed ID: 25224200)
41. The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and of a special subset of multiple myeloma.
Pellat-Deceunynck C; Barillé S; Jego G; Puthier D; Robillard N; Pineau D; Rapp MJ; Harousseau JL; Amiot M; Bataille R
Leukemia; 1998 Dec; 12(12):1977-82. PubMed ID: 9844928
[TBL] [Abstract][Full Text] [Related]
42. Plasma Cell Leukaemia: A Rare Yet Aggressive Plasma Cell Dyscrasia With A Very Poor Response To Conventional Therapy.
Khan N; Raza SS; Khan UI; Hafez I; Abdullah MA; Hassan M; Rukh Hijaz AS; Hussain AK; Nadeem MD
J Ayub Med Coll Abbottabad; 2019; 31(2):272-275. PubMed ID: 31094130
[TBL] [Abstract][Full Text] [Related]
43. Combined proximal tubulopathy, crystal-storing histiocytosis, and cast nephropathy in a patient with light chain multiple myeloma.
Wu CK; Yang AH; Lai HC; Lin BS
BMC Nephrol; 2017 May; 18(1):170. PubMed ID: 28545410
[TBL] [Abstract][Full Text] [Related]
44. Clonal evolution at leukemic relapse of multiple myeloma (secondary plasma cell leukemia) responding to re-treatment with bortezomib-based therapy. A case record.
Bernardeschi P; Pirrotta MT; Montenora I; Giustarini G; Ferreri MI; Simi P; Fiorentini G
Leuk Res; 2010 Apr; 34(4):e104-5. PubMed ID: 19889456
[No Abstract] [Full Text] [Related]
45. Multiple myeloma presenting with hepatosplenomegaly.
Mallavarapu KM; Rajappa S; Linga VG; Gundeti S; Digumarthi R; Uppin SG
J Assoc Physicians India; 2011 Jul; 59():456-8. PubMed ID: 22315756
[TBL] [Abstract][Full Text] [Related]
46. Secondary plasma cell leukaemia (PCL) with plasmablastic morphology.
Xu K; Nacheva E
J Hematop; 2024 Jun; 17(2):117-119. PubMed ID: 38580782
[TBL] [Abstract][Full Text] [Related]
47. Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.
Ganzel C; Rouvio O; Avivi I; Magen H; Jarchowsky O; Herzog K; Cohen Y; Tadmor T; Horwitz NA; Leiba M; Nagler A; Cohen Y; Bulvik S; Polliack A; Rowe JM; Gatt ME;
Leuk Res; 2018 May; 68():9-14. PubMed ID: 29501828
[TBL] [Abstract][Full Text] [Related]
48. [80-year-old patient with dyspnoea, back ache and peripheral oedema. Plasma cell leukemia in multiple myeloma].
Austein T; Demme B
Dtsch Med Wochenschr; 2010 Nov; 135(44):2187-8. PubMed ID: 20979004
[No Abstract] [Full Text] [Related]
49. Plasma cell leukemia: concepts and management.
Liedtke M; Medeiros BC
Expert Rev Hematol; 2010 Oct; 3(5):543-9. PubMed ID: 21083471
[TBL] [Abstract][Full Text] [Related]
50. Successful treatment with bortezomib and dexamethasone for proliferative glomerulonephritis with monoclonal IgG deposits in multiple myeloma: a case report.
Noto R; Kamiura N; Ono Y; Tabata S; Hara S; Yokoi H; Yoshimoto A; Yanagita M
BMC Nephrol; 2017 Apr; 18(1):127. PubMed ID: 28385149
[TBL] [Abstract][Full Text] [Related]
51. Patterns of relapse or progression after bortezomib-based salvage therapy in patients with relapsed/refractory multiple myeloma.
Ahn JS; Jung SH; Yang DH; Bae SY; Kim YK; Kim HJ; Lee JJ
Clin Lymphoma Myeloma Leuk; 2014 Oct; 14(5):389-94. PubMed ID: 24630919
[TBL] [Abstract][Full Text] [Related]
52. [Advances in the Diagnosis and Therapy of Primary Plasma Cell Leukemia -Review].
Wang H; Li JY; Sun C; Zhou X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Dec; 25(6):1837-1841. PubMed ID: 29262927
[TBL] [Abstract][Full Text] [Related]
53. Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
Katodritou E; Terpos E; Kelaidi C; Kotsopoulou M; Delimpasi S; Kyrtsonis MC; Symeonidis A; Giannakoulas N; Stefanoudaki A; Christoulas D; Chatziaggelidou C; Gastari V; Spyridis N; Verrou E; Konstantinidou P; Zervas K; Dimopoulos MA
Am J Hematol; 2014 Feb; 89(2):145-50. PubMed ID: 24123068
[TBL] [Abstract][Full Text] [Related]
54. [Effective PAD (bortezomib, doxorubicin, dexamethasone) treatment of a patient with plasma cell leukaemia that has developed after autologous stem cell transplantation].
Telek B; Méhes L; Batár P; Kiss A; Udvardy M
Orv Hetil; 2008 Oct; 149(41):1957-9. PubMed ID: 18842514
[TBL] [Abstract][Full Text] [Related]
55. Plasma cell leukemia (PCL): A report on 15 patients.
Woodruff RK; Malpas JS; Paxton AM; Lister TA
Blood; 1978 Oct; 52(4):839-45. PubMed ID: 687831
[TBL] [Abstract][Full Text] [Related]
56. [A case of central nervous system myelomatosis with complex chromosome aberrations].
Bang HI; Yoo JY; Kim KH; Park R; Shin JW; Choi TY; Lee SC; Park HS; Won JH
Korean J Lab Med; 2010 Aug; 30(4):334-8. PubMed ID: 20805703
[TBL] [Abstract][Full Text] [Related]
57. [Nonsecretory primary plasma cell leukemia successfully treated with VAD and MP therapy].
Shindo T; Yumoto Y; Yoshida M; Okuda T
Rinsho Ketsueki; 2002 Feb; 43(2):107-11. PubMed ID: 11925872
[TBL] [Abstract][Full Text] [Related]
58. Non-secretory plasma cell leukemia: a rare hematological malignancy.
Singh S; Gupta R; Singh T; Gaiha M
Indian J Pathol Microbiol; 2004 Oct; 47(4):592-3. PubMed ID: 16295407
[No Abstract] [Full Text] [Related]
59. Response to low-dose bortezomib in plasma cell leukemia patients with malignant pleural effusion and ascites: a case report and a review of the literature.
Sekiguchi Y; Shirane S; Imai H; Sugimoto K; Wakabayashi M; Sawada T; Chigira N; Ichikawa K; Komatsu N; Noguchi M
Intern Med; 2012; 51(11):1393-8. PubMed ID: 22687849
[TBL] [Abstract][Full Text] [Related]
60. Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage.
Fernández de Larrea C; Kyle R; Rosiñol L; Paiva B; Engelhardt M; Usmani S; Caers J; Gonsalves W; Schjesvold F; Merlini G; Lentzch S; Ocio E; Garderet L; Moreau P; Sonneveld P; Badros A; Gahrton G; Goldschmidt H; Tuchman S; Einsele H; Durie B; Wirk B; Musto P; Hayden P; Kaiser M; Miguel JS; Bladé J; Rajkumar SV; Mateos MV
Blood Cancer J; 2021 Dec; 11(12):192. PubMed ID: 34857730
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
